Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad domain, discussions of medication safety have traditionally emphasized common side effects and general precautions, often framed within the context of chronic disease management. As the field evolves, there is increasing recognition that certain pharmaceutical exposures may carry rare but serious consequences that require specialized attention. This transition from general health awareness to more focused risk assessment is particularly relevant when examining the relationship between bisphosphonate therapy and adverse outcomes. The scientific evidence connecting Fosamax to osteonecrosis of the jaw represents a critical pivot point, where general health literacy must accommodate occupational and clinical exposure concerns. For healthcare professionals and patients alike, understanding this connection necessitates moving beyond broad health principles toward specific risk stratification. The bridge concept here involves recognizing that what was once considered a routine medication for osteoporosis now demands careful evaluation of individual susceptibility and exposure duration. This shift underscores the importance of integrating specialized knowledge into general health frameworks, ensuring that both legacy information and emerging evidence inform safe therapeutic practices.

Bridging General Health and Specialized Risk: The Fosamax-ONJ Connection

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves areas of exposed bone in the maxillofacial region that persist for weeks to months. Diagnosis is based on clinical examination and imaging, often revealing necrotic bone with surrounding inflammation. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are rooted in bisphosphonate pharmacology. Bisphosphonates like alendronate accumulate in bone, particularly at sites of high turnover, such as the jaw. They inhibit osteoclast activity, which reduces bone remodeling. In the jaw, this suppression of remodeling can impair the ability to repair microdamage and maintain bone health, especially after dental procedures or infections. Multiscale characterization of jawbone in animal models treated with bisphosphonates has shown changes in tissue mineral density distribution and mechanical properties of the jawbone matrix, providing insights into jawbone-specific responses that may contribute to ONJ development (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings help explain why the jaw is particularly vulnerable to bisphosphonate-related complications. Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Warnings and Causation Evidence

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on ONJ (Section 5.4) that describes the condition, associated risk factors, and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similar warnings are present for Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings inform healthcare providers and patients about the risk, but the adequacy of communication to patients may vary. The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, but does not quantify the incidence or provide specific guidance for all clinical scenarios. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, and a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, though ONJ can also occur spontaneously in the absence of bisphosphonate use. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in clinical trials. The timeline between exposure and documented harm is variable. ONJ can develop within days to months after starting Fosamax, but it is often associated with a triggering event such as tooth extraction (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management includes discontinuing the bisphosphonate, addressing local infection, and avoiding further invasive dental procedures until healing occurs.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?

Scientific evidence includes clinical reports, pharmacological mechanisms, and animal studies. Fosamax (alendronate) accumulates in bone, particularly the jaw, and inhibits osteoclast activity, reducing bone remodeling. This can impair repair of microdamage, especially after dental procedures. Animal studies show changes in jawbone mineral density and mechanical properties (https://pubmed.ncbi.nlm.nih.gov/40345077/). The prescribing information for Fosamax includes warnings about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

How is causation between Fosamax and ONJ established in individual cases?

Causation is supported by a temporal relationship: ONJ symptoms can appear days to months after starting Fosamax, often triggered by dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients improve after stopping the drug, and recurrence may occur upon rechallenge. However, ONJ can also occur spontaneously, so individual evaluation is needed.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.